

1 **Context dependent induction of autoimmunity by TNF signaling deficiency**


2

3 **SUPPLEMENTARY TABLES, FIGURES, AND LEGENDS**


4

5 **Supplementary Table 1: Antibodies and reagents**

Reagent	Fluorochromes	Clone	Vendor
CD3	PE Dazle 594/AF700	17A2	Biologend
CD4	BV650	RM4-5	Biologend
CD8	BV711	53-6.7	Biologend
CD19	APC/F750	6D5	Biologend
CD45R/B220	FITC/BV421/BV785	RA3-6B2	Biologend
CD21/CD35	BV605/Biotin/AF647	7G6	BD
CD23	BV711/PE-Cy7/BUV736	B3B4	BD
CD38	AF700/BUV395	90/CD38	BD
CD44	BV785	IM7	Biologend
CD45.1	AF488/PE/APC	A20	eBiosciences/Southern
CD45.2	AF700/PerCP-Cy5.5	104	Biologend
CD62L	BV605	MEL-14	Biologend
CD86	BV785	GL-1	Biologend
CD95	PE-Cy7/AF700	Jo2	BD
CD138	BV421/PE/BV711	281-2	Biologend
ANA	Biotin	NA	Lab made
BACH2	unconjugated	Polyclonal	Novus
Goat anti-Rabbit	PE	Polyclonal	Southern Biotech
Bcl6	AF647	K112-91	BD
CXCR4	PerCP-Cy5.5	L276F12	Biologend
CXCR5	Biotin		
FoxP3	AF488	R16-715	BD
GL7	FITC/AF647/BV421	GL7	BD
Ki67	FITC/AF647/AF700/BV421	16A8	Biologend
IL17A	PerCP-Cy5.5		
IgD	FITC/PE/BV650	11-26c.2a	Biologend
IgM	PE/PE-D594/BV650		BD/Biologend
LiveDead Dye	Aqua fluorescent	NA	Invitrogen/ThermoFisher
Neu5Gc	unconjugated	Poly21469	Biologend
Goat anti-chicken IgY	FITC	Poly24108	Biologend
PD1	PE-Cy7	RMP1-30	Biologend
PNA	Fluorescein/Cy5		Vector Laboratories
PSGL1	BV421	2PH1	BD
Streptavidin	PE/PerCP-Cy5.5/FITC/PB/PE-Cy7	NA	BD
CD11b	AF700/PB	M1/70	Biologend
CD11c	AF700	HL3	BD
CD25	PerCP-Cy5.5	3C7	Biologend
CCR6	BV650	11A9	BD



8 **Supplementary Figure 1. TNF deficiency does not alter B cell phenotype or prevent**
9 **T cell activation in Sle1 mice. A-I.** Bar graphs show the number of spleen cells (A),
10 percent of CD19⁺ (B), transitional T1 (C), T2 (D), Follicular (FO, E), Marginal Zone (MZ,
11 F), IgM⁻IgD⁻ class switched (CS, G) B cells, CD4⁺ T cells (H), and CD4⁺CD44⁺PSGL1⁻
12 PD1^{hi} activated T cells (I) from Sle1 mice of the indicated genotypes. Dots represent
13 individual mice. No differences between the two strains were observed. Mann-Whitney t-
14 test comparing young and aged mice of each strain. ANOVA Kruskal-Wallis with Dunn's
15 multiple comparisons test, * p<0.05: ** p<0.01, *** p<0.001, **** p<0.0001, ns = not
16 significant. y = young (2-3 months), o = old (> 6 months).
17



18

19 **Supplementary Figure 2. CD21/35^{hi} cells in Sle1.TNF^{-/-} and Sle1.TNFR1^{-/-} mice are B**

20 **cells. A.** Immunohistochemistry images (10x) of Sle1 mice of the indicated genotypes


21 show germinal center B cells (GL7), FDCs (CD35/21) and marginal zone macrophages

22 (SIGNR1). GC clusters and FDCs are seen only in Sle1 and Sle1.TNFR2^{-/-} mice. Note

23 the location of CD35 positive cells in a ring around the follicle in TNF and TNFR1 deficient

24 mice. **B.** 3×10^6 bone marrow cells from Sle1 mice (CD45.1) were transplanted
25 intravenously into Sle1.TNFR1^{-/-} mice (CD45.2) 24 hours after lethal irradiation (950
26 rads) and recipients were euthanized after 3 months. Immunohistochemistry images of
27 chimeric spleens show that CD35/21^{hi} cells in the ring around the follicle (red) are B cells
28 of donor (CD45.1) origin (see co-expression of CD35 with B220 and co-expression of
29 CD35 with CD45.1).

30



31

32


33 **Supplementary Figure 3. Abnormal localization of CD4 T cells in Sle1.TNF^{-/-} mice.**

34 **A.** Immunohistochemistry images (20x) show Foxp3⁺ T cells in the LZ of GCs in Sle1

35 mice but scattered localization in Sle1.TNF^{-/-} mice. **B.** PD1⁺ and Bcl6⁺ positive CD4 T cells

36 are located within the GCs of Sle1 mice but are scattered in the T cell zone of Sle1.TNF⁻

37 ⁻ mice.



38

39

40 **Supplementary Figure 4. Vk repertoire in B cell subsets of 3H9.Sle1.TNF^{-/-} and**

41 **3H9.Sle1.TNFR2^{-/-} mice. A-B.** B6 control autoantibody profile and Vk repertoire in B cell

42 subsets of 3H9.Sle1 and 3H9.Sle1.TNF^{-/-} **A-C.** Bar graphs show the relative units of IgG


43 antibodies to chromatin (B), CL/β2GP1 (C) and DNA (D) from sera of 2-3 months old (y)

44 and > 6 months old (o) C57BL/6 and Sle1 mice. ANOVA Kruskal-Wallis with Dunn's

45 multiple comparisons test, * p<0.05; ** p<0.01, *** p<0.001, **** p<0.0001, , ns = not

46 significant. y = young (2-3 months), o = old (> 6 months). **D.** Bar graphs show the relative
47 units of IgG antibodies to dsDNA from sera of Sle1 mice of the indicated genotypes (y =
48 2-3 months old, o > 9 months old). **E-F.** Scree plots show the percent contribution to the
49 chi-square analysis of the most overrepresented *Vk* genes in 3H9⁺ follicular (E) and
50 marginal zone (F) cells from 3H9.Sle1 versus 3H9.Sle1.TNF^{-/-} mice. **G-H.** Percent of *Vk*
51 gene usage in 3H9⁺ follicular (G) and marginal zone (H) cells from 3H9.Sle1 and
52 3H9.Sle1.TNF^{-/-} mice. Fisher Exact test rxc table, p = 0.671 (E), p<0.0004 (F).

53



54

55 **Supplementary Figure 5. Extrafollicular response is associated with clinical**

56 **disease in Sle1.Yaa.TNF^{-/-} mice. A.** Percent of mice with proteinuria of <100mg/dl as


57 they age. **B.** IgG and C3 deposition in glomeruli of male Sle1.Yaa and Sle1.Yaa.TNF^{-/-}

58 mice but not in male Sle1.TNF^{-/-} mice. **C.** Representative H&E images show

59 glomerulonephritis and glomerular hypertrophy in > 6-month-old male Sle1.Yaa and

60 Sle1.Yaa.TNF^{-/-} mice but not in male Sle1.TNF^{-/-} mice. **D.** Bar graphs showed summary

61 of Glomerular (Glo) and interstitial (Int) scores from renal H&E stains. Dotted line indicates
62 maximum values in young Sle1 controls. **E.** Representative plots show PNA, CD38, Ki67
63 and Bcl6 expression in splenic CD95⁺GL7⁺ B cells. **F.** Percent of PNA^{lo}CD38⁺ cells in
64 CD19⁺CD95⁺GL7⁺ cells in > 6-month-old male Sle1.Yaa, Sle1.TNF^{-/-} and Sle1.Yaa.TNF⁻
65 ^{-/-} mice. Dots on bar graphs represent individual mice. ANOVA Kruskal-Wallis with Dunn's
66 multiple comparisons test, * p<0.05: ** p<0.01.



67

68 **Supplementary Figure 6. T dependent immunization with and without IFNA does**

69 **not induce GC formation in Sle1.TNF^{-/-} mice.** Plots show percent of CD95⁺GL7⁺ in

70 CD19⁺ B cells (A) and CD44⁺PSGL1^{lo}PD1^{hi} in CD4⁺ T cells (B) in Sle1 (white bars and


71 Sle1.TNF^{-/-} mice (grey bars) after immunization as indicated. Dots on bar graphs

72 represent individual mice. ANOVA Kruskal-Wallis with Dunn's multiple comparisons test,

73 ns = not significant.

74

75



76

77 **Supplementary Figure 7. Failure to acquire GL7 expression in Sle1.TNF^{-/-} mice is**
 78 **due to sustained expression of Neu5Gc and is B cell extrinsic. A.**
 79 Immunohistochemistry images (20x) show reduction of Neu5GC expression on GL7⁺ B
 80 cells in GC of Sle1 mice (top), but not in Sle1.TNF^{-/-} (bottom) mice. **B-C.** Summary bar
 81 graphs of flow analysis shows MFI of Neu5Gc (B) and GL7 (C) on splenic CD95⁺GL7⁺ B
 82 cells. **D.** Immunohistochemistry image (20x) shows reduction of Neu5GC expression on
 83 PNA⁺ B cells in GC of NZM mice (top) that is attenuated in DKO (bottom) mice. **E.**
 84 Follicular CD19⁺ splenic B cells from Sle1.TNF^{-/-} mice were sort purified and placed in

85 culture with Nojima supporter cells and IL4. Cells were collected at the indicated days
86 and analyzed for CD95 and GL7 expression. Plots show cells gated on singlet live CD3⁻
87 CD19⁺ cells. **F.** Summary bar graph of flow cytometry analysis shows the GL7 MFI of
88 CD95⁺GL7⁺ cells. Dots on bar graphs represent individual mice. Mann-Whitney t-test, *
89 p<0.05.